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Abstract
Diabetes  mellitus  is  a  major  health problem that  affects  approximately 171 million
people globally. One of its most severe complications is the development of diabetic
foot ulcers (DFU). Ischemic and neurophatic lesions are of major importance for DFU
onset;  however,  it  is  the  infection  by  multidrug-resistant  and  biofilm-producing
microorganisms,  along  with  local  microenvironmental  conditions  unfavorable  to
antibiotics action that ultimately cause infection chronicity and lower limbs amputa‐
tion.  Novel  therapeutic  protocols  for  DFU  management  are  extremely  urgent.
Bacteriophages,  probiotics  and  antimicrobial  peptides  (AMP)  have  recently  been
proposed as alternatives to currently available antibiotics. Bacteriophages are viruses
that  specifically  infect  and  multiply  within  bacterial  cells.  Their  ability  to  diffuse
through polymeric matrixes makes them particularly efficient to eradicate biofilm-
based  bacteria.  Promising  results  were  also  observed  with  probiotic  therapy.
Probiotics are well-characterized strains with the ability to compete with pathogen‐
ic  microorganisms  and  modulate  the  host  immune  response.  AMP  are  molecules
produced  by  living  organisms  as  part  of  their  innate  immune  response.  Unlike
conventional antibiotics, AMP also act as immunomodulators and resistance to AMP
was  rarely  observed,  supporting  their  potential  as  therapeutic  agents.  These
innovative  therapeutic  strategies  may  in  the  future  substitute  or  complement
antibiotherapy,  ultimately  contributing  for  the  decrease  in  multidrug-resistant
bacteria dissemination.
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1. Introduction
Diabetes mellitus is a serious health problem in rapid expansion worldwide. It is estimated that
there are 171 million diabetic patients worldwide and this number is expected to double by the
year 2030 [1]. Diabetic foot ulcers (DFU) are one of the most frequent complications of diabe‐
tes, resulting from a complex interaction of factors, namely ischemia and neuropathy [2].
Neuropathy, which is characterized by modifications in sensitive and autonomic functions,
causes ulceration due to trauma or excessive pressure in a deformed foot without protective
sensibility. Autonomic neuropathy causes dryness of the skin by decreasing sweating, and
therefore the vulnerability of the skin to break down increases. Once the protective layer of
skin is damaged, deep tissues are exposed to bacterial colonization [3].
Diabetes-associated ischemia is caused by peripheral arterial disease. Poor arterial inflow
decreases blood supply to ulcer area and is associated with reduced oxygenation, nutrition,
and ulcer healing [3].
These ulcers are frequently colonized by pathogenic bacteria and infection is facilitated by
immunological deficits related to diabetes [4], rapidly progressing to deeper tissues, increas‐
ing the presence of necrotic tissue, rendering amputation inevitable [5]. In fact, diabetic patients
frequently require minor or major amputations of the lower limbs (15-27%) [2], which not only
contribute dramatically to high morbidity among diabetic patients, but is also associated with
severe clinical depression and increased mortality rates [6].
Although ischemic and neuropathic changes have the initial role in DFU pathophysiology, in
the majority of cases it is the infection by multidrug-resistant microorganisms and the
unfavorable microenvironmental conditions to the action of antibiotics that leads to amputa‐
tion [5].
Diabetes-associated foot ulcer infections are predominantly polymicrobial and several
bacterial genera can be part of the DFU microbiota, namely Staphylococcus, Pseudomonas,
Streptococcus, Enterococcus, Corynebacterium, Acinetobacter, Prevotella, Porphyromonas, and
members of the family Enterobacteriaceae. The predominant Gram-positive and Gram-nega‐
tive species present in DFU are Staphylococcus aureus and Pseudomonas aeruginosa, respective‐
ly [7–9].
There is, to date, little understanding of the ecology of such chronic infections, but bacterial
biofilms seem to play a major role [10]. These are ubiquitous and complex structures consist‐
ing of an interactive community of polymicrobial cells embedded in a self-produced extracel‐
lular matrix of hydrated polymeric substances, such as proteins, polysaccharides, nucleic acids
and others, irreversibly attached to the biological surface of the ulcer. These characteristics
make them recalcitrant to the action of most antibiotics and also resistant to the innate immune
system [11].
administration of biofilm-based infections generally requires local surgical procedures as well
as antibiotic administration. However, in infected DFU, because of deficient vascularization,
antibiotics frequently reach the local ulcer microenvironment only at subtherapeutic concen‐
Microbial Biofilms - Importance and Applications252
trations [5]. Even when topically applied, antibiotics rarely reach bacteria that reside within
mature biofilms at therapeutic concentrations [12].
Biofilm formation is a major mechanism of adaptation that is able to protect bacteria from
antibiotics, due to several physiological traits. Firstly, biofilm spatial structure provides a
protective coat against antimicrobial compounds. Secondly, in most cases, biofilms are
polymicrobial, formed by complex mixtures of different species. It was proposed that, in such
biofilms, the chemical interactions that occur between polymeric substances produced by
different bacterial strains might lead to a more viscous matrix, impairing the contact be‐
tween the bacterial cell wall and the antibiotic. Lastly, the production of degradative en‐
zymes by different pathogenic species can act synergistically against antimicrobial
compounds. These biofilm features are responsible for a reduced diffusion of the antibiotic
within the biofilm matrix [13, 14].
In addition, patients suffering from DFU face the emergence and dissemination of antibiotic
resistant bacteria, which is not a recent biological phenomenon. Seventy years ago, after the
discovery of penicillin and the beginning of the antibiotic era, Alexander Fleming noticed the
emergence of bacterial strains resistant to penicillin. Indeed, resistance began to appear in
target microorganisms, including S. aureus isolates from hospitals, a few years after the
introduction of penicillin into medical practice [15]. Fleming described the occurrence of
antibiotic resistance and warned the scientific and medical community of this phenomenon in
his Nobel Prize lecture in 1945 [16].
Several causes can explain the emergence and dissemination of antibiotic resistance. Firstly,
the overuse and, most importantly, the misuse of antibiotics in different but interconnected
areas, like human and veterinary medicine, agriculture and animal production. Secondly, the
effects of antibiotic compounds in the environment are not yet completely described and
understood. Finally, antibiotic compounds are stable and static chemical substances that are
used to fight living and evolving bacterial cells [17]. Microorganisms, namely bacteria, are
ubiquitous and interact with all other living beings. Considering that nature is a highly
complex system supported by extremely dynamic interactions and exchanges between all its
elements, the emergence and evolution of bacterial populations able to resist against antibi‐
otic substances is not surprising. In fact, over the last decades, microbiologists have demon‐
strated the influence that antibiotics exert upon bacterial populations. Previously seen as
miracle drugs, capable of virtually eradicating all species of bacteria, antibiotics are now seen
as substances with limited antimicrobial capacity and multifaceted proprieties. These
compounds have the ability to induce or inhibit different bacterial responses and to influ‐
ence bacterial virulence and survival strategies [18, 19].
As mentioned above, biofilm formation is a well-known virulence factor of some bacterial
strains that, along with many other advantages, confers them a protective layer against adverse
elements. Recently, it was demonstrated that some antibiotics are able to induce this adapta‐
tive strategy. In 2005, when Hoffman et al. [18] were testing the efficacy of aminoglycosides, a
widely exploited antibacterial therapeutic agent, against biofilm-forming bacteria, they
observed an unexpected bacterial response. Aminoglycosides not only did not eliminate the
P. aeruginosa strain used in the study, but also stimulated their ability to form biofilm. In fact,
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they demonstrated that aminoglycosides interact with the P. aeruginosa aminoglycoside
response regulator gene, arr, which encodes for an inner-membrane phosphodiesterase
essential to the regulation of cyclic di-guanosine monophosphate levels, which represents a
bacterial second messenger that regulates cell surface adherence [18]. Later on, Kaplan et al.
[19] also reported that in Escherichia coli, not only sub inhibitory antibiotic concentrations but
also disinfectants such as chlorhexidine are responsible for the induction of biofilm forma‐
tion. From their work, one can conclude that, for some bacterial strains, biofilm formation can
be a specific defensive reaction to the presence of antibiotics.
Despite all the evidences showing that biofilms provide advantages to microorganisms,
namely enhanced resistance towards environmental stresses including the presence of
antimicrobial compounds, many antibiotics that are currently in use were developed, tested,
and regulated using in vitro tests against planktonic bacteria.
It is known that microbial cells growing within a biofilm are physiologically distinct from
planktonic cells of the same strain. The overall resistance level in biofilms is distinct from the
one observed at a cellular level [20]. As a consequence, the antimicrobial concentration
required to inhibit biofilms can be up to hundreds or even a thousand times higher than the
corresponding concentration necessary to eliminate free-living bacterial cells [21]. Such
phenomena cannot be overlooked in the development of novel strategies to combat infec‐
tious diseases.
Taking into account that biofilm formation is a threatening characteristic of the microbiome
that colonizes diabetic foot wounds, it is not unexpected that in the past few decades a major
problem in treating DFU infections has been the increasing rate of colonisation by antibiotic
resistant pathogens. This is the case of methicillin-resistant S. aureus (MRSA), and to a lesser
degree, glycopeptide-intermediate S. aureus, vancomycin-resistant enterococci, extended-
spectrum β-lactamase- or carbapenamase–producing gram-negative bacilli, and highly
resistant strains of P. aeruginosa. In fact, the infection by polymicrobial communities of
multidrug-resistant bacteria is an important cause of DFU healing impediment [7, 22–27].
The rates of isolation of these multidrug-resistant pathogens vary widely among geographi‐
cal area and treatment center. However, the increasing incidence of multidrug-resistant
microorganisms together with the incapacity of antibiotics to act on resistant and biofilm-
producing bacteria at therapeutical concentrations emphasizes the importance of develop‐
ing new treatment strategies to effectively eradicate these infections.
Considering that biofilms were only described by the scientific community by the end of the
twentieth century, it is comprehensible that research on biofilms is still an expanding area [28].
The lack of understanding of the mechanisms behind the biofilm mode of life has impaired
the development of antimicrobial compounds that specifically operate on biofilm polymicro‐
bial communities [28]. However, in recent years, the increased failure in infectious diseases
therapeutic protocols and the dissemination of antibiotic resistance has demonstrated the
importance of developing such substances and several novel therapeutic strategies, namely
bacteriophages, probiotics and antimicrobial peptides (AMP), are recently been explored and
proposed as potential alternatives to eradicate bacterial biofilms in DFU.
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2. Bacteriophages
Bacteriophages were discovered almost a century ago by two independent microbiologists,
Twork in 1915 in the United Kingdom and D’Herelle in 1917 in France. D’Herelle named these
bacteria-eating entities as bacteriophages and explored them as antibacterial agents [29, 30].
Bacteriophages are bacteria-specific viruses that infect and multiply within bacterial cells. In
contrast to lysogenic bacteriophages, the replication of lytic bacteriophages and release of the
newly formed virus particles always involves lysis of the host bacterial cell. Bacteriophage
therapy is the use of lytic bacteriophages to reduce or eliminate pathogenic bacteria [31].
Lytic bacteriophages seem to be efficient therapeutical agents in biofilm microenvironment
due to several particular characteristics: specificity and efficiency in lysing pathogenic bacteria;
absence of pathogenicity to man and animals; efficiency over bacteria organized in polymer‐
ic matrixes, namely biofilms; action in microaerophilic environments with high bacterial load;
and rapid and economical accessible production capability [32, 33].
Bacteriophage therapy has become a broadly relevant technology for veterinary, agricultural
and food microbiological applications; however, the treatment of human infections with
bacteriophage-based protocols attracts the greatest interest [34].
Bacteriophages are viruses that specifically infect prokaryotic bacterial cells. In fact, the
prokaryotic biochemical machinery that enables the interaction between bacteriophages and
bacterial cells has particular characteristics that are not present in eukaryotic cells. For instance,
the outer membrane receptors of bacterial cells, with which bacteriophage capsid coat or
molecular appendages first connect with the purpose of being anchored on the bacterial cell
wall, as well as the polymerases required for the bacteriophage genome replication, are specific
of prokaryotic bacterial cells and are structurally and functionally different from those
presented by eukaryotic cells [31]. For that reason, bacteriophages can only directly interact
and infect bacterial cells, and not eukaryotic cells. The bacterio-specificity features allow
classifying bacteriophages as ‘safe’ for use in eukaryotic organisms, namely plants and
animals, including humans.
The use of bacteriophages as antibacterial agents for suppurative infections began shortly after
their discovery, with Bruynoghe’s and Maisin’s application for treating S. aureus skin infec‐
tions [35]. However, following the discovery and general application of antibiotics, interest in
the therapeutic uses of bacteriophages waned. Recently, the increase in antibiotic-resistant
bacterial strains has reinvigorated enthusiasm about these bacteria-specific viruses [36]. This
interest is particularly true in cases in which bacteriophages can be applied topically, as is the
case of DFU.
Recently, a topically delivered bacteriophage suspension was tested for its antimicrobial
activity and wound healing capability against ulcers chronically infected with S. aureus, P.
aeruginosa and Acinetobacter baumannii. In this study, conducted by Mendes et al. in 2013 [37],
the bacteriophage suspension was applied in debrided infected cutaneous wounds and
microbiologic, histological and planimetric parameters were evaluated. It was shown that the
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bacteriophage treatment successfully decreased bacterial colony counts and improved wound
healing, as indicated by smaller epithelial and dermal gaps. The bacteriophage therapy
protocol developed was proven to be an effective methodology in the treatment of two animal
models of Diabetes mellitus, rodents and porcines [37].
The same bacteriophage suspension also demonstrated in vitro activity against both plank‐
tonic cells and established biofilms. Using metabolic activity as a measure of cell viability, it
was observed that bacteriophage treatment significantly increased cell impairment within
biofilms. Moreover, bacteriophage exposure repeated every four hours caused a further
decrease in cell activity [9].
There is still much to unravel regarding bacteriophage therapy. For instance, not all phages
are suitable for clinical application. More information is required, namely detailed studies of
potentially useful phages with respect to their interaction with target bacteria and their genetic
content.
Nonetheless, despite the paucity of experimental data regarding bacteriophage therapy in
DFU, a consensus appears to have emerged on the feasibility of this potential alternative to
treat biofilm-infected DFU.
3. Probiotics
The increasing global antimicrobial drug resistance problem led to an urge in researching
alternatives to drug therapies, making the concept of bacteriotherapy more interesting and
pertinent than ever. Bacteriotherapy is a promising alternative approach to fight infections by
employing harmless bacteria to displace pathogenic microorganisms [38].
The concept of ‘probiotic’ arose in 1907 from a hypothesis proposed by Noble Prize-winning
Ilya Mechnikov. At the turn of the twentieth century, Mechnikov noticed that peasant
populations in Bulgaria had increased average life spans in comparison with wealthier
European populations [39]. He also observed that yogurt and other fermented milk products
were a substantial part of their diets and described the beneficial effects of the ‘Bulgarian
bacillus’ present in those foods [40, 41]. These healthy bacteria, later classified Lactobacillus
bulgaricus, helped digestion, impaired the putrefactive effects of gastrointestinal metabolism,
and contributed to the improvement of the immune system [41].
Mechnikov was not the only one to notice the health benefits of lactic acid bacteria. A few years
before, in 1899, another important discovery was made at the Pasteur Institute in Paris. Henri
Tissier demonstrated that children suffering from diarrhea had a low number of bacteria
characterized by a peculiar Y-shaped morphology. On the other hand, these “bifid” bacteria
were abundant in the gut flora of healthy breast-fed infants. Moreover, Tissier demonstrated
that the administration of these Y-shaped bacteria, later classified Bifidobacterium, to patients
with diarrhea allowed them to re-establish a healthy intestinal microbiome [42].
The definition of probiotic as well as their characteristics have evolved in the last century and
nowadays probiotics are defined By the Food and Agriculture Organization and the World
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Health Organization as: ‘live microorganisms that, when administered in adequate amounts,
confer a health benefit on the host” [43]. Probiotics are either a single strain or a mixture of
commensal microorganisms with the ability to outcompete pathogenic bacteria through
several mechanisms of action. The two most common are direct modification of the microbi‐
al populations and modulation of host immune system [43].
Direct modification of the microbiome includes competition with pathogenic bacteria for
adhesion to epithelial receptor, production of antimicrobial substances like acids, hydrogen
peroxide and bacteriocins, and inhibition of toxic substances produced by pathogens.
Immunomodulation includes strengthening of host immune response, promotion of anti-
inflammatory action, and enhancement of the wound healing process by stimulating the
accumulation of inflammatory cells like lymphocytes, macrophages and polymorphonuclear
cells in the site of wound [44].
As one would expect, not all commensal bacteria are suitable to be used as a probiotic. The
screening and selection of probiotics includes a rigorous evaluation of the probiotic candi‐
date strain in order to determine whether it fulfills all the required criteria.
Firstly, it is important to assess its safety. An evaluation that includes strain identification and
typing, antimicrobial resistance profiling, and determination of virulence and pathogenic
properties, including metabolic activities associated with toxic compounds production, is
mandatory [45]. Secondly, it is relevant to determine its technological potential. It is essen‐
tial for a probiotic strain to be genetically stable and bacteriophage-resistant. In addition, it
must present viability during processing and storage and be adequate for large-scale produc‐
tion [46]. Thirdly, it is required to establish its physiological properties. To survive the host
inner environment, which is rather complex and hostile, a probiotic strain must possess specific
characteristics such as gastric acid and bile tolerance and mucosal surface adhesion stability
[47]. Lastly, the functional properties must be evaluated. Validated and documented health
effects are mandatory, namely antagonistic activity towards pathogens, immunomodulatory
activity, and anticarcinogenic properties. Some probiotic strains are also able to interfere with
the host cholesterol and lactose metabolism, preventing damages by its metabolites [48].
Probiotics have already been exploited for prevention as well as treatment of a number of
health disorders including irritable bowel syndrome, hypersensitivity such as food allergies,
hypercholesterolemia, renal failure, gastritis and gut infection, parasitic infections, urogeni‐
tal infections, colorectal cancer, and dental disorders [49, 50]. Since the putative probiotic
mechanisms of action should be the same in the peripheral wounds as they are in other parts
of the body, these can be considered as a potential DFU treatment alternative.
Lactic acid bacteria (LAB), in particular Lactobacillus and Bifidobacterium species, have been
extensively used as probiotic strains. The genus Lactobacillus is formed by ubiquitous and
usually harmless bacteria. In animals, including humans, they are present in the gastrointes‐
tinal and genitourinary tracts where they act as health promoters [51]. The genus Bifidobacte‐
rium includes anaerobic bacteria that produce acetic and lactic acid without release of carbon
dioxide. Bifidobacterium is the third most abundant genus in the complex microbiome of the
human intestinal tract where it exerts beneficial functions of paramount importance [52].
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However, other species of bacteria, and even some fungi, also present probiotic properties,
such as Enterococcus faecium, Bacillus cereus, E. coli strain Nissle, Propionibacterium freudenrei‐
chii, Propionibacterium acnes and the yeasts Saccharomyces cerevisae and Saccharomyces boulardii
[53–55].
LAB commonly produce antimicrobial substances with effect against gastric and intestinal
pathogens and compete for cell surface and mucin binding sites [56]. Recent studies have
demonstrated the efficacy of LAB-based therapy for DFU infections control. A study on
effectiveness of bacteriotherapy using Lactobacillus plantarum on infected chronic DFU
demonstrated that topical application of this bacterial culture induced debridement, granula‐
tion tissue formation and total healing in half of the diabetic patients treated [57, 58].
Lactobacillus fermentum also showed promising applications in treating DFU infections. When
co-incubated in vitro with S. aureus and P. aeruginosa, L. fermentum reduced the cytotoxicity and
biofilm formation ability of several pathogenic strains [59].
Additional studies have suggested that Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacil‐
lus casei, Lactobacillus acidophilus and Lactococcus lactis are also promising probiotics with the
ability to naturally eliminate pathogenic microorganisms, including MRSA clinical isolates
[60].
In the last years, probiotics have been widely studied and all these recent data point out the
beneficial effects of probiotics to human and animal health. Naturally, no probiotic strain will
provide all the proposed benefits. However, one can no longer ignore the emergence of
probiotics as a novel approach to fight multidrug-resistant and biofilm-producing bacteria
commonly present in DFU.
4. Antimicrobial peptides
Antimicrobial peptides are major components of the host innate immune system that act as
endogenous antibiotics [61, 62]. These multifunctional molecules are produced by living
organisms from all kingdoms, including bacteria, fungi, plants, insects and vertebrates, as part
of their defense strategy against pathogens. Most AMP act as the first defense barrier against
dissemination of a wide spectrum of microorganisms, such as bacteria, fungi, viruses and
protozoan parasites [62].
In addition to their antimicrobial activity, AMP serve as modulators of the immune system
and even show antitoxic activity, since they neutralize bacterial toxins, including lipopolysac‐
charide lipid A [63, 64]. Some AMP are also able to prevent biofilm formation and act on pre-
formed biofilms [65].
The majority of AMP are polypeptides with ten to forty amino acid residues; however, some
can have up to a hundred. AMP are amphipathic molecules, with two regions in their structure,
a polar or hydrophilic region and a nonpolar or hydrophobic region. Due to the presence of
multiple lysine, arginine, and histidine residues, the polar region of AMP is cationically
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charged. On the other hand, hydrophobicity derives from the abundant presence of hydro‐
phobic amino acids, such as tryptophan, tyrosine and phenylalanine [66, 67].
The distinctive physical-chemical properties of AMP are what confers them their potential as
antimicrobial compounds. It has been generally accepted that AMP exert their bactericidal
activity through electrostatic interactions with the negatively charged bacterial cytoplasmic
membrane, followed by permeabilization of the membrane, which causes cell lysis. Membrane
permeabilization can occur through pore formation in the lipid membrane, membrane
dissolution, narrowing of the membrane bilayer or lipid-peptide domain formation [68]. The
AMP amphipathic structure, namely their cationic and hydrophobic regions, interacts with
the negatively charged phospholipids present in the surface of the microorganisms’ cytoplas‐
mic membranes. Bacterial membranes are rich in lipids such as phosphatidilglycerol and
cardiolipin, whereas host cells have eukaryotic membranes that are rich in phosphatidylcho‐
line, cholesterol, and sphingomyelin [69].
It is the difference in the lipids that constitute the membranes of bacteria and host cells that
allows AMP to selectively target the microbial cells over mammal cells and confers them the
criterion of safety to be use in eukaryotic organisms, including humans.
Additionally to their role as membrane disruptors, several studies have also suggested
alternative targets for AMP. In fact, it was proven that some AMP are able to translocate into
the cytoplasm of pathogens and attack intracellular targets. This way, AMP impair essential
bacterial metabolic processes, including nucleic acids synthesis and cell wall assembly [70–72].
AMP can present multiple and simultaneous mechanisms of action, including both mem‐
brane permeabilization and intracellular effects. This property is probably the reason why they
present antimicrobial activity against such a wide range of pathogens.
Regarding their immunological functions, AMP are also known as host-defense peptides [73–
76]. By interacting with a variety of host cell receptors, AMP promote the recruitment of
leukocytes to the site of infection through direct chemotactic activity and stimulation of
chemokine production by leukocytes, epithelial cells, and other cell types [77, 78]. Finally, some
AMP also play a role in angiogenesis and wound healing [79, 80].
The production of AMP is not limited to multicellular organisms; bacteria can also synthe‐
size AMP that are active against other bacteria. These AMP of bacterial origin include non-
ribosomally synthesized peptides such as gramicidins, and ribosomally synthesized peptides
such as bacteriocins, and have been used for years [81, 82]. Gramicidin S is a cyclic decapep‐
tide produced by Bacillus aneurinolyticus and has been used as a topical antimicrobial agent
against Gram-positive bacteria since 1946 [83]. Nisin is a bacteriocin produced by L. lactis that
acts primarily against Gram-positive bacteria and has been used safely as a food preserva‐
tive for over 50 years [84].
Several studies have analyzed the in vitro activity of different AMP against DFU clinical
isolates. In 2013, Okuda et al. [85] evaluated the antimicrobial activity and mode of action of
three bacteriocins, nisin A, lacticin Q, and nukacin ISK-1, against a clinically isolated and
biofilm-producing MRSA strain. Nukacin ISK-1, produced by Staphylococcus warneri, present‐
ed only bacteriostatic effects. However, both nisin A and lacticin Q, produced by L. lactis,
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showed bactericidal efficacy against planktonic and biofilm cells [85]. Synthetic cationic
antimicrobial peptides, namely NP101 and NP108, also showed in vitro activity against
bacterial species commonly associated with DFU infections, such as S. aureus and P. aerugino‐
sa, as demonstrated by O’Driscoll et al. [86] in 2013. These results suggest that bacteriocins that
act on biofilm-producer cells are highly suitable for the treatment of DFU infections.
However, there are some limitations in the use of AMP as a clinical alternative for Antibiot‐
ics, in spite of the fact that bacteria resistance to AMP is rare, in opposition to what is ob‐
served towards classic antibiotics [87]. This characteristic of AMP is likely to be related to the
ionic interaction between the positively charged AMP and the negatively charged bacteria
membrane. Since these interactions are not dependent of specific protein binding sites, in order
to develop resistance to AMP, bacteria would have to change the basic structure, namely the
lipid bilayer, of its cytoplasmic membrane [88]. Moreover, attachment of the AMP with the
bacterial membrane and consequent cell lysis happens in such a short period of time, render‐
ing the possibility to develop AMP resistance quite scarce [89]. However, there are reports of
distinct species of bacteria, which present resistance towards AMP. The mechanisms of
resistance include degradation of AMP through secretion of proteases; removal of AMP from
their site of action via efflux pumps; production of inhibitors that bind to AMP and prevent
them from reaching their target; and modulation of AMP gene expression [90–92].
Another obstacle to the successful implementation of AMP as an alternative to conventional
antibiotics is the production costs. AMP discovery and development is time consuming,
reaching up to 10 years, and can cost millions of euros or dollars. In fact, production costs are
estimated to be approximately 50-400 American dollars per gram of amino acid [93].
Even so, AMP are still a promising alternative to antibiotics. A possible solution to reduce costs
associated with AMP production is the reduction of the peptide size, maintaining its antimi‐
crobial activity [94]. Moreover, AMP exhibit physiological and functional advantages over
other molecules that make them so attractive to be used in clinical practice. For instance,
physiological concentrations of AMP in vivo are much lower than the minimal inhibitory
concentrations required for its antimicrobial activity in vitro [95]. In fact, AMP are antimicro‐
bial agents with a broad-spectrum activity displayed at micromolar concentrations, usually in
the 1-50 µg/ml range [96]. A plausible justification for this fact may be the synergistic effect
that some AMP possess, which enhances their antimicrobial activity in vivo [97].
For all these reasons, the development of AMP-based therapies to eliminate microbial
pathogens, such as those present in DFU infections, is extremely promising and deserves
further exploration.
5. Conclusive remarks
The severity of diabetic foot infections and the economic burden associated with its preven‐
tion, treatment and control have compelled scientists and clinicians to invest substantial time
and effort in not only understanding how these mechanisms work, but also how they can
interfere with them.
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As mentioned before, a major factor responsible for healing impediment of DFU are infec‐
tions by multidrug-resistant or biofilm-producing bacteria. Dissemination of these strains,
coupled with disinvestment in new antibiotics development, calls for increasing research to
find new approaches to prevent and control these pathogens. In this chapter, the potentiali‐
ties of bacteriophage viruses, probiotic strains and antimicrobial peptides as novel strategies
for management of DFU, were reviewed. Several studies, conducted by independent re‐
search teams, have demonstrated promising results, both in vitro as in vivo, regarding their
competence to eradicate the pathogenic microorganisms present in DFU. However, further
investigation is required so that in the future, these strategies could be applied in clinical
practice alongside with conventional therapeutics.
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